Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

NCT04260126 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Neoplasms, Head and Neck

Interventions

COMBINATION_PRODUCT: Pembrolizumab (KEYTRUDA®) and PDS0101

Sponsor

PDS Biotechnology Corp.

Collaborators

[object Object]